Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allspice aqueous extract (AAE) is a preclinical-stage, plant-derived anti-cancer formulation prepared from the dried, unripe berries of *Pimenta dioica* (Allspice). Its key active ingredient is ericifolin (eugenol 5-O-β-galloylglucopyranoside), a polyphenolic compound. AAE has demonstrated anti-proliferative and anti-tumor activity against prostate cancer and breast cancer (including triple-negative breast cancer) in vitro and in vivo. Its mechanism of action involves the inhibition of androgen receptor (AR) transcription, down-modulation of estrogen receptor alpha (ERα), and the inhibition of the Akt/mTOR signaling pathway, which induces cytotoxic autophagy. Developed primarily in academic research settings, such as the University of Miami, AAE remains a preclinical research tool with no approved clinical uses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allspice aqueous extract.